“We have two excellent treatments for superficial venous reflux,” The VEINS 2025 audience hears

Sharing late-breaking secondary outcomes through 12 months from a randomised trial, Manj Gohel (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) concluded at The VEINS 2025 (1–2 November, Las Vegas, USA) that cyanoacrylate closure with the VenaSeal system (Medtronic) is comparable to the standard of care for saphenous reflux. 

The randomised trial was part of the Spectrum programme and compared cyano­acrylate closure with VenaSeal to endothermal abla­tion for saphenous reflux. Conducted at 17 sites across eight countries and beginning in February 2020, the study enrolled patients with CEAP C2–C5 disease. Outcomes at 12 months included anatomic vein closure, patient and physician assess­ments of quality of life, safety, time to return to work, and reintervention rates.  

Summarising key safety results, Gohel shared that no new types of VenaSeal-specific adverse events were recorded, and that all were easily managed. In addition, he noted that all VenaSeal-specific adverse events occurred early, with none arising between six and 12 months in the study.  

Also on safety, Gohel shared that the low incidence rates of VenaSeal-specific complications agree with the randomised controlled trial literature, and that there were no serious adverse events related to a VenaSeal device or procedure through 12 months. 

Gohel also highlighted comparable effectiveness between cyanoacrylate closure and endothermal ablation, noting that patients receiving treatment with the VenaSeal system experienced similar anatomic vein closure rates compared to the global standard of care. 

Finally, Gohel revealed a patient experience with cyanoacrylate closure similar to that of endothermal ablation. Specifically, he noted that patient satisfaction, quality of life, and symptom assessment improved after treatment with the VenaSeal system. 

Closing his presentation, Gohel concluded that these latest results showing comparable outcomes between cyanoacrylate closure and endothermal ablation “confirm that we have two excellent treatments for superficial venous reflux”.